Susquehanna Fundamental Investments’s CorMedix CRMD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,743	Closed	-$183K	–	1728
2021 Q2	$183K	Buy	26,743 +2,743	+11%	+$21.8K	﹤0.01%	1505
2021 Q1	$240K	Hold	24,000	–	–	﹤0.01%	1355
2020 Q4	$178K	Buy	24,000 +11,100	+86%	+$75.5K	﹤0.01%	1369
2020 Q3	$78K	Buy	+12,900	New	+$64.8K	﹤0.01%	1303

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Susquehanna Fundamental Investments's CRMD Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of CorMedix (CRMD) in Q3 2021, closing a stake of 26,743 shares — an estimated $183K sold.

Susquehanna Fundamental Investments first reported a position in CRMD in Q3 2020 and held it in 4 quarters. The position peaked at $240K in Q1 2021. 79 funds tracked by Wall St. Rank hold CRMD as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining CorMedix position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 26,743 CorMedix shares in Q3 2021, an estimated $183K.
Susquehanna Fundamental Investments first reported a position in CorMedix in Q3 2020 and held it in 4 quarters.
Susquehanna Fundamental Investments's CorMedix position peaked at $240K in Q1 2021.
79 funds tracked by Wall St. Rank held CorMedix as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.